| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ewa Kozela, Christeene Haj, Lumir Hanuš, Mukesh Chourasia, Avital Shurki, Ana Juknat, Nathali Kaushansky, Raphael Mechoulam, Zvi Voge. HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Chemical biology & drug design. vol 87. issue 1. 2016-12-13. PMID:26259697. |
hu-446 and hu-465, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic t cells. |
2016-12-13 |
2023-08-13 |
mouse |
| Ewa Kozela, Christeene Haj, Lumir Hanuš, Mukesh Chourasia, Avital Shurki, Ana Juknat, Nathali Kaushansky, Raphael Mechoulam, Zvi Voge. HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Chemical biology & drug design. vol 87. issue 1. 2016-12-13. PMID:26259697. |
cannabidiol (cbd), the non-psychoactive cannabinoid, has been previously shown by us to decrease peripheral inflammation and neuroinflammation in mouse experimental autoimmune encephalomyelitis (eae) model of multiple sclerosis (ms). |
2016-12-13 |
2023-08-13 |
mouse |
| Joshua A Lile, Michael J Wesley, Thomas H Kelly, Lon R Hay. Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol. Behavioural pharmacology. vol 27. issue 2-3 Spec Issue. 2016-12-13. PMID:26313650. |
these results suggest that one mechanism by which gabapentin might facilitate cannabis abstinence is by producing effects that overlap with those of cannabinoids. |
2016-12-13 |
2023-08-13 |
Not clear |
| Paul F Smith, Yiwen Zhen. Cannabinoids, cannabinoid receptors and tinnitus. Hearing research. vol 332. 2016-12-13. PMID:26433054. |
this review explores the question of whether cannabinoid receptor agonists are likely to be pro- or anti-epileptic in the cochlear nucleus and therefore whether cannabinoids and cannabis itself are likely to make tinnitus better or worse. |
2016-12-13 |
2023-08-13 |
Not clear |
| Caitlin E Carey, Arpana Agrawal, Bo Zhang, Emily D Conley, Louisa Degenhardt, Andrew C Heath, Daofeng Li, Michael T Lynskey, Nicholas G Martin, Grant W Montgomery, Ting Wang, Laura J Bierut, Ahmad R Hariri, Elliot C Nelson, Ryan Bogda. Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. Journal of abnormal psychology. vol 124. issue 4. 2016-12-13. PMID:26595473. |
monoacylglycerol lipase (mgll) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: evidence from an endocannabinoid system-level analysis. |
2016-12-13 |
2023-08-13 |
Not clear |
| Caitlin E Carey, Arpana Agrawal, Bo Zhang, Emily D Conley, Louisa Degenhardt, Andrew C Heath, Daofeng Li, Michael T Lynskey, Nicholas G Martin, Grant W Montgomery, Ting Wang, Laura J Bierut, Ahmad R Hariri, Elliot C Nelson, Ryan Bogda. Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. Journal of abnormal psychology. vol 124. issue 4. 2016-12-13. PMID:26595473. |
despite evidence for heritable variation in cannabis involvement and the discovery of cannabinoid receptors and their endogenous ligands, no consistent patterns have emerged from candidate endocannabinoid (ecb) genetic association studies of cannabis involvement. |
2016-12-13 |
2023-08-13 |
Not clear |
| Caitlin E Carey, Arpana Agrawal, Bo Zhang, Emily D Conley, Louisa Degenhardt, Andrew C Heath, Daofeng Li, Michael T Lynskey, Nicholas G Martin, Grant W Montgomery, Ting Wang, Laura J Bierut, Ahmad R Hariri, Elliot C Nelson, Ryan Bogda. Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. Journal of abnormal psychology. vol 124. issue 4. 2016-12-13. PMID:26595473. |
these results are consistent with rodent models implicating 2-arachidonoylglycerol (2-ag), an endogenous cannabinoid metabolized by the enzyme encoded by mgll, in the etiology of stress adaptation related to cannabis dependence, but require further replication. |
2016-12-13 |
2023-08-13 |
Not clear |
| Lia Costa, Cristina Amaral, Natércia Teixeira, Georgina Correia-da-Silva, Bruno M Fonsec. Cannabinoid-induced autophagy: Protective or death role? Prostaglandins & other lipid mediators. vol 122. 2016-12-13. PMID:26732541. |
cannabinoids are active compounds of cannabis sativa and the most prevalent psychoactive substance is Δ(9)-tetrahydrocannabinol (thc). |
2016-12-13 |
2023-08-13 |
Not clear |
| Shirley Y Hill, Bobby L Jones, Stuart R Steinhauer, Nicholas Zezza, Scott Stiffle. Longitudinal predictors of cannabis use and dependence in offspring from families at ultra high risk for alcohol dependence and in control families. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 171B. issue 3. 2016-12-13. PMID:26756393. |
the association between young adult patterns of cannabis use or cannabis abuse/dependence was tested with genetic variation in the cannabinoid gene, cnr1, the ankk1-drd2 gene, and childhood developmental trajectories of p300. |
2016-12-13 |
2023-08-13 |
Not clear |
| Katarzyna Fijał, Małgorzata Fili. Clinical/Therapeutic Approaches for Cannabinoid Ligands in Central and Peripheral Nervous System Diseases: Mini Review. Clinical neuropharmacology. vol 39. issue 2. 2016-12-13. PMID:26818043. |
cannabinoids, the components of cannabis sativa linnaeus, interact with cb1 and cb2 receptors, which are located both in the central nervous system and in the periphery and thus may exert a widespread biological activity in the body. |
2016-12-13 |
2023-08-13 |
Not clear |
| Thomas Schwitzer, Raymund Schwan, Karine Angioi-Duprez, Anne Giersch, Vincent Laprevot. The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications. Neural plasticity. vol 2016. 2016-12-13. PMID:26881099. |
the main effects of cannabis are mediated by two major exogenous cannabinoids: ∆9-tetrahydroxycannabinol and cannabidiol. |
2016-12-13 |
2023-08-13 |
human |
| Giovanna Morello, Roberta Imperatore, Letizia Palomba, Carmine Finelli, Giuseppe Labruna, Fabrizio Pasanisi, Lucia Sacchetti, Lorena Buono, Fabiana Piscitelli, Pierangelo Orlando, Vincenzo Di Marzo, Luigia Cristin. Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling. Proceedings of the National Academy of Sciences of the United States of America. vol 113. issue 17. 2016-12-13. PMID:27071101. |
ox-a is crucial for the control of wakefulness and energy homeostasis and promotes, in ox-1r-expressing cells, the biosynthesis of the endogenous counterpart of marijuana's psychotropic and appetite-inducing component Δ(9)-tetrahydrocannabinol, i.e., the endocannabinoid 2-arachidonoylglycerol (2-ag), which acts at cb1r. |
2016-12-13 |
2023-08-13 |
mouse |
| S Giacoppo, T Soundara Rajan, M Galuppo, F Pollastro, G Grassi, P Bramanti, E Mazzo. Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis. European review for medical and pharmacological sciences. vol 19. issue 24. 2016-11-02. PMID:26744883. |
the present study was designed to test the effects of intraperitoneal administration of cannabidiol (cbd), the main non-psychotropic cannabinoid of cannabis sativa (cs), in an experimental model of ms. |
2016-11-02 |
2023-08-13 |
Not clear |
| David D Aguilar, Andrea Giuffrida, Daniel J Lodg. THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. Journal of psychopharmacology (Oxford, England). vol 30. issue 2. 2016-10-31. PMID:26510449. |
such information is important for understanding why marijuana and synthetic cannabinoid use may be contraindicated in schizophrenia patients while endocannabinoid enhancement may provide a novel therapeutic approach. |
2016-10-31 |
2023-08-13 |
rat |
| Amir Englund, Zerrin Atakan, Aleksandra Kralj, Nigel Tunstall, Robin Murray, Paul Morriso. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 2. 2016-10-31. PMID:26577065. |
cannabis is mostly grown under illegal and unregulated circumstances, which seems to favour a product increasingly high in its main cannabinoid ∆-9-tetrahydrocannabinol (thc). |
2016-10-31 |
2023-08-13 |
human |
| David W Volk, David A Lewi. The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26210060. |
in addition, how interactions between these alterations in the endocannabinoid system and those in other inhibitory neurons in the prefrontal cortex in subjects with schizophrenia might increase the liability to adverse outcomes with cannabis use is considered. |
2016-10-28 |
2023-08-13 |
human |
| Alán Alpár, Vincenzo Di Marzo, Tibor Harkan. At the Tip of an Iceberg: Prenatal Marijuana and Its Possible Relation to Neuropsychiatric Outcome in the Offspring. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26549491. |
notably, cannabinoid receptors serve as molecular targets for the psychotropic plant-derived cannabis constituent Δ(9)-tetrahydrocannainol, as well as synthetic derivatives (designer drugs). |
2016-10-28 |
2023-08-13 |
human |
| F Markus Leweke, Juliane K Mueller, Bettina Lange, Cathrin Rohlede. Therapeutic Potential of Cannabinoids in Psychosis. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26852073. |
second, the modulation of endocannabinoid levels by use of the phytocannabinoid cannabidiol and selective fatty acid amide hydrolase inhibitors has been proposed, and the antipsychotic properties of cannabidiol are currently being investigated in humans. |
2016-10-28 |
2023-08-13 |
Not clear |
| Valentina Lorenzetti, Nadia Solowij, Murat Yüce. The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26858212. |
the role of cannabinoids in neuroanatomic alterations in cannabis users. |
2016-10-28 |
2023-08-13 |
human |
| Valentina Lorenzetti, Nadia Solowij, Murat Yüce. The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Biological psychiatry. vol 79. issue 7. 2016-10-28. PMID:26858212. |
we examine whether neuroanatomic alterations are 1) consistently observed in samples of regular cannabis users, particularly in cannabinoid receptor-high areas, which are vulnerable to the effects of high circulating levels of thc, and 2) associated either with greater levels of cannabis use (e.g., higher dosage, longer duration, and earlier age of onset) or with distinct cannabinoid compounds (i.e., thc and cbd). |
2016-10-28 |
2023-08-13 |
human |